Zenith Health Care Ltd
Incorporated in 1993, Zenith Health
care Ltd is engaged in manufacturing
and trading of pharma products[1]
- Market Cap ₹ 18.9 Cr.
- Current Price ₹ 3.52
- High / Low ₹ 5.85 / 3.05
- Stock P/E
- Book Value ₹ 1.40
- Dividend Yield 0.00 %
- ROCE 3.12 %
- ROE 0.81 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
Cons
- Stock is trading at 2.51 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -1.11% over past five years.
- Promoter holding is low: 28.7%
- Company has a low return on equity of 1.56% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.27 | 3.64 | 3.46 | 4.79 | 9.51 | 9.83 | 11.98 | 13.74 | 22.36 | 13.13 | 14.47 | 11.33 | 11.16 | |
| 3.54 | 3.68 | 3.69 | 4.73 | 8.95 | 9.63 | 11.43 | 13.38 | 21.91 | 13.10 | 14.23 | 11.24 | 11.31 | |
| Operating Profit | -0.27 | -0.04 | -0.23 | 0.06 | 0.56 | 0.20 | 0.55 | 0.36 | 0.45 | 0.03 | 0.24 | 0.09 | -0.15 |
| OPM % | -8.26% | -1.10% | -6.65% | 1.25% | 5.89% | 2.03% | 4.59% | 2.62% | 2.01% | 0.23% | 1.66% | 0.79% | -1.34% |
| 0.10 | 0.05 | 0.12 | 0.08 | 0.13 | 0.21 | 0.30 | 0.46 | 0.52 | 0.38 | 0.26 | 0.43 | 0.55 | |
| Interest | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Depreciation | 0.24 | 0.35 | 0.35 | 0.30 | 0.28 | 0.25 | 0.25 | 0.25 | 0.36 | 0.28 | 0.21 | 0.23 | 0.28 |
| Profit before tax | -0.41 | -0.35 | -0.47 | -0.17 | 0.40 | 0.16 | 0.59 | 0.56 | 0.60 | 0.12 | 0.28 | 0.28 | 0.12 |
| Tax % | -31.71% | -31.43% | -36.17% | -11.76% | 32.50% | 18.75% | 3.39% | 19.64% | 48.33% | 33.33% | 25.00% | 78.57% | |
| -0.27 | -0.24 | -0.31 | -0.15 | 0.27 | 0.14 | 0.57 | 0.44 | 0.31 | 0.08 | 0.20 | 0.07 | -0.06 | |
| EPS in Rs | -0.05 | -0.04 | -0.06 | -0.03 | 0.05 | 0.03 | 0.11 | 0.08 | 0.06 | 0.01 | 0.04 | 0.01 | -0.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 12% |
| 5 Years: | -1% |
| 3 Years: | -20% |
| TTM: | -11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | -36% |
| 3 Years: | -42% |
| TTM: | -167% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -19% |
| 3 Years: | -13% |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 3% |
| 3 Years: | 2% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 | 5.37 |
| Reserves | 0.68 | 0.48 | 0.17 | 0.02 | 0.29 | 0.43 | 1.03 | 1.47 | 1.78 | 1.86 | 1.96 | 2.03 | 2.16 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.78 | 0.60 | 1.04 | 0.74 | 1.43 | 1.14 | 2.14 | 1.92 | 4.52 | 2.02 | 2.56 | 3.48 | 3.19 | |
| Total Liabilities | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.72 |
| 1.37 | 2.17 | 1.93 | 1.75 | 1.81 | 1.62 | 1.70 | 1.80 | 1.75 | 1.50 | 1.40 | 1.55 | 1.58 | |
| CWIP | 0.79 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.17 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 4.67 | 4.28 | 4.65 | 4.38 | 5.28 | 5.34 | 6.67 | 6.96 | 9.92 | 7.75 | 8.49 | 9.33 | 9.14 | |
| Total Assets | 6.83 | 6.45 | 6.58 | 6.13 | 7.09 | 6.96 | 8.54 | 8.76 | 11.67 | 9.25 | 9.89 | 10.88 | 10.72 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | 0.19 | 0.23 | 0.23 | 0.00 | -0.06 | 1.95 | -1.47 | 1.32 | -0.92 | 1.74 | 0.67 | |
| -0.44 | -0.14 | 0.01 | -0.12 | 0.00 | -0.05 | -0.50 | -0.19 | -0.23 | -0.03 | -1.88 | -1.09 | |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Cash Flow | -0.51 | 0.05 | 0.24 | 0.11 | 0.00 | -0.09 | 1.44 | -1.65 | 1.09 | -0.95 | -0.14 | -0.41 |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 218.78 | 183.50 | 132.92 | 84.58 | 54.88 | 33.79 | 31.08 | 44.89 | 53.05 | 64.22 | 57.26 | 77.96 |
| Inventory Days | 192.90 | 170.89 | 297.41 | 179.91 | 102.66 | 125.86 | 99.18 | 145.11 | 104.78 | 147.45 | 86.65 | 152.87 |
| Days Payable | 132.38 | 86.27 | 177.67 | 78.95 | 82.53 | 47.61 | 84.31 | 71.22 | 37.63 | 51.11 | 38.08 | 91.59 |
| Cash Conversion Cycle | 279.29 | 268.12 | 252.65 | 185.54 | 75.01 | 112.04 | 45.95 | 118.78 | 120.21 | 160.55 | 105.84 | 139.24 |
| Working Capital Days | 296.91 | 246.68 | 208.87 | 136.40 | 82.13 | 96.17 | 48.14 | 98.02 | 50.93 | 116.76 | 60.54 | 69.59 |
| ROCE % | -6.79% | -5.71% | -8.08% | -2.93% | 7.42% | 2.79% | 9.82% | 8.61% | 8.72% | 1.81% | 3.98% | 3.12% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
12 Nov - Paper Cutting of Published Unaudited Financial Result for the Quater and Half Year ended 30th September, 2025
- Unaudited Standalone Financial Results Of The Company Forthe Second Quarter And Half Year Ended 30 September2025 11 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting
11 Nov - Unaudited results for quarter and half-year ended 30 Sep 2025 approved on 11 Nov 2025.
-
Board Meeting Intimation for Board Meeting Intimation For Considering The Un-Audited Financial Results For The Quarter And Half Yearly Ended September 30, 2025
3 Nov - Board meeting on 11 Nov 2025 to approve Q2/H1 unaudited results for period ended 30 Sep 2025; trading window closed.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Oct - Submission of Declaration of RTA Under Regulation 74(5) of Depositories And Participants Regulation, 2018
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
ZHL is in the business of manufacturing pharmaceutical formulations in the forms of general and beta lactum Tablets, Capsules, Oral liquid, and Injectables. The company offers contract manufacturing of all dosage forms.
The services include purchasing of raw materials, production, packaging, and quality control, and offering solid dosage forms in General and Beta-Lactam Tablets, Capsules, Oral Liquids, and Dry Powder Oral Suspension.